These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17217378)

  • 1. Expression profiling of PC-3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostate.
    Patrikainen L; Porvari K; Kurkela R; Hirvikoski P; Soini Y; Vihko P
    Eur J Clin Invest; 2007 Feb; 37(2):126-33. PubMed ID: 17217378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells.
    Liu T; Bauskin AR; Zaunders J; Brown DA; Pankhurst S; Russell PJ; Breit SN
    Cancer Res; 2003 Aug; 63(16):5034-40. PubMed ID: 12941831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.
    Bauskin AR; Brown DA; Junankar S; Rasiah KK; Eggleton S; Hunter M; Liu T; Smith D; Kuffner T; Pankhurst GJ; Johnen H; Russell PJ; Barret W; Stricker PD; Grygiel JJ; Kench JG; Henshall SM; Sutherland RL; Breit SN
    Cancer Res; 2005 Mar; 65(6):2330-6. PubMed ID: 15781647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
    Meyer-Siegler KL; Iczkowski KA; Vera PL
    BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia.
    Kakehi Y; Segawa T; Wu XX; Kulkarni P; Dhir R; Getzenberg RH
    Prostate; 2004 Jun; 59(4):351-6. PubMed ID: 15065082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array.
    Porkka KP; Visakorpi T
    J Pathol; 2001 Jan; 193(1):73-9. PubMed ID: 11169518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
    Halvorsen OJ; Oyan AM; Bø TH; Olsen S; Rostad K; Haukaas SA; Bakke AM; Marzolf B; Dimitrov K; Stordrange L; Lin B; Jonassen I; Hood L; Akslen LA; Kalland KH
    Int J Oncol; 2005 Feb; 26(2):329-36. PubMed ID: 15645116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
    Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
    BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
    Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
    Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.
    Rasiah KK; Kench JG; Gardiner-Garden M; Biankin AV; Golovsky D; Brenner PC; Kooner R; O'neill GF; Turner JJ; Delprado W; Lee CS; Brown DA; Breit SN; Grygiel JJ; Horvath LG; Stricker PD; Sutherland RL; Henshall SM
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):711-6. PubMed ID: 16614113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
    Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
    Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
    Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
    Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and nuclear localization of ErbB3 in prostate cancer.
    Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
    Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.